Compound News and Research

RSS

Research team has found a new way to streamline gene isolation to determine their functions

A single strand of plant or animal DNA may contain tens of thousands of genes, each programmed to produce a specific protein essential for the growth or survival of the organism. The challenge for geneticists is to isolate individual genes and determine their function -- a painstaking process often requiring years of laboratory trial and error.

31 Mar 2004

Faster new cloning technique - transcript-based cloning

A single strand of plant or animal DNA may contain tens of thousands of genes, each programmed to produce a specific protein essential for the growth or survival of the organism. The challenge for geneticists is to isolate individual genes and determine their function – a painstaking process often requiring years of laboratory trial and error.

30 Mar 2004

Natural compound in snake venom for treatment of malignant tumours

Researchers at the University of South Australia have made a major discovery using a natural compound in snake venom that shows very promising anti-cancer effects. The compound works by activating the destruction of cells which make up the blood vessels that supply nutrients to tumours, according to Associate Professor Tony Woods from UniSA’s School of Pharmaceutical, Molecular and Biomedical Sciences.

30 Mar 2004

Human Genome Sciences can begin cardiovascular disease research

Human Genome Sciences, Inc.announced today that it has received a clinical development milestone payment from its partner, GlaxoSmithKline, related to the initiation of Phase 1 clinical trials of 677116 for the treatment of cardiovascular disease. 677116 is a small-molecule inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme associated with the formation of atherosclerotic plaques.

30 Mar 2004

Genencor Sells Its Therapeutic Vaccine Program to Innogenetics

Genencor International, Inc. today announced that it has agreed to sell its therapeutic vaccine program to Belgian biotechnology company Innogenetics N.V. Innogenetics will develop and commercialize current product candidates in Genencor’s vaccine product portfolio as well as future products based on intellectual property and technology held by Genencor.

30 Mar 2004

IPM takes over Microbicide development to protect against sexual transmission of HIV

International Partnership for Microbicides (IPM) today announced that it has reached a farsighted agreement with Tibotec Pharmaceuticals Ltd, a subsidiary of Johnson & Johnson. The aim is to develop the promising compound TMC120 as a safe and effective microbicide to help protect women from infection with HIV. This agreement marks the first collaboration in the microbicide field between a major healthcare company and a public-private partnership such as IPM.

29 Mar 2004

Immunomodulator induces long-term anti-tumor activity

EntreMed, Inc., a clinical-stage biopharmaceutical company developing therapeutic candidates primarily for the treatment of cancer, today reported that three months following administration with ENMD 0996, preclinical animal models showed inhibition of metastases. Data presented demonstrated that ENMD 0996 specifically blocks the activity of basic fibroblast growth factor (FGF-2), a naturally-occurring protein that stimulates angiogenesis, but had no effect on other angiogenesis stimulators.

29 Mar 2004

Oral chemotherapy agent Orathecin™ (rubitecan) capsules accepted by FDA for filing

SuperGen Inc. announced today that the Food and Drug Administration (FDA) has officially accepted the Orathecin™ (rubitecan) capsules’ New Drug Application (NDA) for filing. Orathecin, an investigational anticancer compound, is an oral chemotherapy agent that has been investigated as a treatment for pancreatic cancer patients who have failed at least one prior chemotherapy.

26 Mar 2004

Asian poison ivy like plant may stop prostate cancer

The croton plant, long known to oriental herbalists and homeopaths as a purgative, has an oil in its seeds that shows promise for the treatment of prostate cancer – the second leading cause of cancer death in men in the United States. The active ingredient in the oil is 12-O-tetradecanoylphorbol-13-acetate, a compound generally known as TPA.

22 Mar 2004

New treatment for heart attacks

A team led by scientists at The Scripps Research Institute has developed a potential new treatment for heart attacks. The therapy inhibits fluid leakage from cardiac blood vessels following a heart attack and thereby significantly prevents long-term heart damage and improves survival.

22 Mar 2004